NCT03710707已完成1 期
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive
- •Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H&Y Stage I, II, or III.
- •sPD subgroup without a LRRK2 mutation; PD LRRK2 subgroup with LRRK2 mutation
- •Screening dopamine transporter (DAT) SPECT scan with a DAT deficit consistent with Parkinson's disease
- •Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific study assessments
排除标准
- •Any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening
- •Abnormal Vitals including Respiratory Rate, Body Temperature, and Blood Pressure
- •Pulmonary Function Tests (PFTs) (FVC <60% predicted, FEV1 <50% predicted, FEV1:FVC ratio <0.6, DLCO <70% predicted)
- •Clinically significant neurologic disorder other than Parkinson's disease, including history of stroke, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening
- •Montreal Cognitive Assessment (MoCA) score of <24 at screening
研究组 & 干预措施
DNL201 low dose
Experimental
干预措施: DNL201 (Drug)
DNL201 high dose
Experimental
干预措施: DNL201 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: Randomization to Day 42
Number of Subjects with vital sign abnormalities
时间窗: Randomization to Day 42
Number of Subjects with electrocardiogram (ECG) abnormalities
时间窗: Randomization to Day 42
Number of Subjects with laboratory test abnormalities
时间窗: Randomization to Day 42
Number of Subjects with clinically significant neurological examination abnormalities
时间窗: Randomization to Day 42
次要结局
- Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL201(Randomization to Day 28)
- Pharmacokinetic measure of CSF concentrations of DNL201(Randomization to Day 28)
- Pharmacodynamic measure of pS935 in whole blood and/or PBMCs(Randomization to Day 28)
- Pharmacokinetic measure of trough plasma observed concentration (Ctrough) of DNL201(Randomization to Day 28)
- Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL201(Randomization to Day 28)
- Pharmacodynamic measure of pRab10 in PBMCs(Randomization to Day 28)
- Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL201(Randomization to Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseParkinson's DiseaseNCT04056689Biogen36
已完成
1 期
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich AtaxiaFriedreich AtaxiaNCT05573698Design Therapeutics, Inc.32
已完成
1 期
A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsPainNCT05866055Vertex Pharmaceuticals Incorporated30
已完成
1 期
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy ParticipantsAcute PainNCT05347394Vertex Pharmaceuticals Incorporated100
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy VolunteersHealthy VolunteersNCT06625541AnnJi Pharmaceutical Co., Ltd.57